Laboratory of Biological Modeling, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):7107-12. doi: 10.1073/pnas.0911095107. Epub 2010 Mar 29.
Ligand-mediated gene induction by steroid receptors is a multistep process characterized by a dose-response curve for gene product that follows a first-order Hill equation. This behavior has classically been explained by steroid binding to receptor being the rate-limiting step. However, this predicts a constant potency of gene induction (EC(50)) for a given receptor-steroid complex, which is challenged by the findings that various cofactors/reagents can alter this parameter in a gene-specific manner. These properties put strong constraints on the mechanisms of gene induction and raise two questions: How can a first-order Hill dose-response curve (FHDC) arise from a multistep reaction sequence, and how do cofactors modify potency? Here we introduce a theoretical framework in which a sequence of steps yields an FHDC for the final product as a function of the initial agonist concentration. An exact determination of all constants is not required to describe the final FHDC. The theory predicts mechanisms for cofactor/reagent effects on gene-induction potency and maximal activity and it assigns a relative order to cofactors in the sequence of steps. The theory is supported by several observations from glucocorticoid receptor-mediated gene induction. It identifies the mechanism and matches the measured dose-response curves for different concentrations of the combination of cofactor Ubc9 and receptor. It also predicts that an FHDC cannot involve the DNA binding of preformed receptor dimers, which is validated experimentally. The theory is general and can be applied to any biochemical reaction that shows an FHDC.
甾体激素受体介导的配体基因诱导是一个多步骤过程,其基因产物的剂量反应曲线遵循一级希夫方程。这种行为经典地解释为受体与配体结合是限速步骤。然而,这预测了给定受体-配体复合物的基因诱导效价(EC50)是恒定的,这与以下发现相矛盾,即各种辅助因子/试剂可以以基因特异性的方式改变该参数。这些特性对基因诱导机制施加了很强的限制,并提出了两个问题:多步骤反应序列如何产生一级希夫剂量反应曲线(FHDC),以及辅助因子如何改变效价?在这里,我们引入了一个理论框架,其中一个步骤序列产生最终产物的 FHDC,作为初始激动剂浓度的函数。不需要确定所有常数来描述最终的 FHDC。该理论预测了辅助因子/试剂对基因诱导效价和最大活性的影响机制,并按步骤序列对辅助因子进行了相对排序。该理论得到了糖皮质激素受体介导的基因诱导的几个观察结果的支持。它确定了机制,并匹配了不同浓度的辅助因子 Ubc9 和受体组合的测量剂量反应曲线。它还预测,FHDC 不可能涉及预先形成的受体二聚体的 DNA 结合,这在实验上得到了验证。该理论是通用的,可以应用于任何显示 FHDC 的生化反应。